501-75-7

Usage

Uses

Used in Nutritional Supplements:
2-(1-methylimidazol-4-yl)ethanamine is used as a nutritional supplement in high fiber diets. It plays a role in promoting gluconeogenesis, which is the process of producing glucose from non-carbohydrate sources, and inhibiting glycolysis in muscle, which is the breakdown of glucose to release energy.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, 2-(1-methylimidazol-4-yl)ethanamine may be utilized for its potential therapeutic applications due to its histamine-like structure. This could include the development of drugs targeting various conditions where histamine plays a role, such as allergies or certain neurological disorders.
Used in Research and Development:
2-(1-methylimidazol-4-yl)ethanamine can also be used as a research compound in the development of new drugs and therapies. Its unique chemical structure may provide insights into the design of novel molecules with specific biological activities.

Upstream product

• 41065-00-3 1-Methyl-4-cyanomethyl-imidazol 
• 673-49-4 N-acetylhistamine 
• 77-78-1 dimethyl sulfate 
• 51720-37-7 2-methyl-5-oxo-5,6,7,8-tetrahydroimidazo<1,5-c>pyrimidinium iodide 
• 51-45-6 histamine 
• 14509-66-1 5,6,7,8-tetrahydro-5-oxoimidazo[1,5-c]pyrimidine 
• 51-45-6 histamine 
• 18502-05-1 4-cyanomethylimidazole 

Downstream Products

• 64403-25-4 3-methyl-3,4,6,7-tetrahydro-5H-imidazo<4,5-c>pyridine 
• 58177-25-6 4-hydroxyethyl-1-methyl-1H-imidazole 
• 210238-13-4 (2R,3R,4S,5R)-2-{6-Benzylamino-2-[2-(1-methyl-1H-imidazol-4-yl)-ethylamino]-purin-9-yl}-5-(2-methyl-2H-tetrazol-5-yl)-tetrahydro-furan-3,4-diol Formate 
• 210238-69-0 (2R,3R,4S,5R)-2-{6-Benzylamino-2-[2-(1-methyl-1H-imidazol-4-yl)-ethylamino]-purin-9-yl}-5-(2-isopropyl-2H-tetrazol-5-yl)-tetrahydro-furan-3,4-diol Formate 
• 210238-07-6 (2R,3R,4S,5R)-2-{6-(2,2-Diphenyl-ethylamino)-2-[2-(1-methyl-1H-imidazol-4-yl)-ethylamino]-purin-9-yl}-5-(2-methyl-2H-tetrazol-5-yl)-tetrahydro-furan-3,4-diol Formate 
• 210238-21-4 (2R,3R,4S,5R)-2-{2-[2-(1-Methyl-1H-imidazol-4-yl)-ethylamino]-6-phenethylamino-purin-9-yl}-5-(2-methyl-2H-tetrazol-5-yl)-tetrahydro-furan-3,4-diol Formate 
• 210238-15-6 (2R,3R,4S,5R)-2-{6-(2-Cyclohexyl-ethylamino)-2-[2-(1-methyl-1H-imidazol-4-yl)-ethylamino]-purin-9-yl}-5-(2-methyl-2H-tetrazol-5-yl)-tetrahydro-furan-3,4-diol Formate 
• 210238-11-2 (2R,3R,4S,5R)-2-{6-(3-Iodo-benzylamino)-2-[2-(1-methyl-1H-imidazol-4-yl)-ethylamino]-purin-9-yl}-5-(2-methyl-2H-tetrazol-5-yl)-tetrahydro-furan-3,4-diol Formate 
• 1225591-15-0 1-[(R)-2-(4-butyryl-4-cyclohexylpiperidin-1-yl)-1-(4-methoxybenzyl)-2-oxoethyl]-3-[2-(1-methyl-1H-imidazol-4-yl)ethyl]urea 
• 1419868-80-6 C₃₁H₃₅N₇O₃ 

Relevant academic research and scientific papers

Preparation method of 5-tert-butyl-4-ethyl-3-methyl-dihydro-3H-imidazopyridine-(4H)-dicarboxylate

The invention relates to a preparation method of 5-tert-butyl-4-ethyl-3-methyl-dihydro-3H-imidazopyridine-(4H)-dicarboxylate, and mainly solves the technical problem that a suitable industrial synthesis method does not exist at present. The method comprises the following three steps: 1, reacting a compound 1 in hydrochloric acid to obtain a compound 2; 2, reacting the compound 2 with an ethyl glyoxylate toluene solution in acetonitrile to obtain a compound 3; and 3, reacting the compound 3 with Boc anhydride and triethylamine in dichloromethane to obtain a final compound 4. The reaction formula is shown in the specification.

2-(1H-Imidazol-4-yl)ethanamine and 2-(1H-pyrazol-1-yl)ethanamine side chain variants of the IGF-1R inhibitor BMS-536924

A series of IGF-1R inhibitors is disclosed, wherein the (m-chlorophenyl)ethanol side chain of BMS-536924 (1) is replaced with a series of 2-(1H-imidazol-4-yl)ethanamine and 2-(1H-pyrazol-1-yl)ethanamine side chains. Some analogs show improved IGF-1R poten

PURINE DERIVATIVES AS AGONISTS OF THE ADENOSINE A2A RECEPTOR

The invention relates to novel adenosine receptor agonists of formula (I), methods for their manufacture and their use as medicaments.

CXCR4 chemokine receptor binding comounds

The present invention relates to compounds that bind to chemokine receptors, and having the formula wherein each A, X, Y, R1, R2 and R3 are substituents. The present invention also relates to methods of using such compounds, such as in treating HIV infection and inflammatory conditions such as rheumatoid arthritis. Furthermore, the present invention relates to methods to elevate progenitor and stem cell counts, as well as methods to elevate white blood cell counts, using such compounds.

NEW OLIGOMERIC CONJUGATES LIABLE TO TRANSFER BIOLOGICAL MOLECULES INTO CELLS

The invention relates to a positively charged oligomeric conjugate, containing an oligomer with a polymerization degree (PD) from 5 to 50, preferably 10 to 40 and more preferably 20, formed from monomeric components having free NH3 in a number equal to or higher than 50 % of the polymerization degree. In particular, the invention provides new oligomeric conjugates of histidylated oligolysine liable to allow the transfer of oligonucleotides, peptides and oligosides into cells.

The selective synthesis of 1-methyl-1H-histamines

The selective synthesis of 1-methyl-1H-4-histamine (1) and 1-methyl-1H-5-histamine (2) via 5-oxo-5,6,7,8-tetrahydroimidazo[1,5-c]pyrimidine (3) from commercially available histamine hydrochloride salt is described.

A Heteroditopic Hexa-imidazole 'Encapsulating' Podand and a Facially Differentiated Hexadentate Ligand

Syntheses of the facially differentiated tris-imidazole triamine (10) and of the novel 'hetero'-ditopic hexa-imidazole ligand (11), from histamine (3), are described.

Anti-ulcer and antisecretory activity of selected imidazopiperidines

New thioureas and ureas with an interesting anti-ulcer and antisecretory activity are presented. The chemical synthesis, determination of the structure, and structure-activity relationships of the compounds are discussed.